A bone infusion — usually zoledronic acid, given once a year through a vein — is one of the most effective treatments for osteoporosis, cutting fracture risk significantly with a single 15-minute appointment. It’s not painful, doesn’t require daily pills, and most people tolerate it well after a short flu-like reaction to the first dose. Here’s exactly what to expect, from booking to aftercare.
- Zoledronic acid (brand name Aclasta/Reclast) is the most common osteoporosis infusion, given as a single yearly dose
- The infusion itself takes 15–20 minutes and is done as a day-case appointment — no overnight stay needed
- Around 30–40% of people get flu-like symptoms after their first infusion; this is much less common from the second dose onwards
- Blood tests and kidney function checks are required before every infusion
- It’s an alternative to daily or weekly tablets for people who struggle with oral bisphosphonates or their side effects
- Treatment is typically given for 3 years, then reassessed with a DEXA scan
Infusion treatment is one of several options in modern osteoporosis treatment — and for many patients, particularly those who can’t tolerate oral bisphosphonates, it’s the preferred route. If you’re weighing up tablets versus infusions, this guide walks through the practical side of what an infusion day actually involves.
What is a bone infusion?
A bone infusion delivers medication — almost always a bisphosphonate called zoledronic acid — directly into a vein through a drip. It works the same way as bisphosphonate tablets like alendronic acid: it slows down the cells (osteoclasts) that break down old bone, giving bone-building cells time to keep density stable or improve it. The difference is delivery. Instead of remembering a weekly tablet with strict food and posture rules, you receive the entire year’s dose in one sitting.
Zoledronic acid infusions are usually given once a year (the brand names you’ll see are Aclasta or Reclast). A related infused drug, ibandronic acid, is sometimes given every three months, though it’s less commonly used in the UK. Both belong to the bisphosphonate family — the same drug class as oral tablets — so the underlying mechanism and most of the precautions are shared.
Who is offered an infusion instead of tablets?
Infusions are usually considered when:
- Oral bisphosphonates have caused significant heartburn, acid reflux, or oesophageal irritation
- You have swallowing difficulties or a condition affecting the upper gastrointestinal tract
- You’ve struggled to stick with the strict dosing rules tablets require (empty stomach, full glass of water, staying upright for 30–60 minutes)
- You have a history of poor absorption, for example after certain types of gastric surgery
- Bone density has continued to fall despite tablet treatment, and a stronger delivery method is needed
It isn’t automatically “stronger” than tablets in terms of fracture protection — trial data shows broadly comparable efficacy between oral and IV bisphosphonates at equivalent doses — but for people who can’t tolerate or reliably take tablets, it removes the biggest barrier to treatment actually working: adherence.
What happens before your infusion
Before your first (and every subsequent) infusion, your clinical team will check:
- Kidney function (eGFR) — zoledronic acid is not given if kidney function is significantly reduced
- Calcium and vitamin D levels — you need adequate levels before treatment, and low vitamin D is usually corrected first with supplementation
- Dental health — a dental check is recommended beforehand, particularly if any extractions or invasive dental work are planned, because of a rare risk of osteonecrosis of the jaw
- Hydration status — you’ll be asked to drink water before arriving to protect your kidneys during the infusion
This is also the point where your DEXA scan results and fracture history are reviewed to confirm an infusion is the right next step.
What happens on infusion day
The appointment itself is straightforward and typically takes under an hour door-to-door, with the infusion running for 15–20 minutes:
- A cannula (small tube) is placed in a vein, usually in your arm or hand
- The zoledronic acid is delivered slowly through a drip
- You’ll be monitored throughout and for a short period afterwards
- The cannula is removed and you’re free to go — most people drive themselves home or return to normal activities the same day
Side effects: the flu-like reaction, explained
The most talked-about side effect is an “acute phase reaction” — flu-like symptoms including fever, muscle aches, joint pain, headache, and fatigue, starting within 1–3 days of the infusion and usually resolving within 3 days. It affects roughly 30–40% of people after their first infusion, far fewer after the second, and is uncommon from the third dose onwards.
It happens because the immune system reacts to the drug the first time it encounters it — it isn’t an allergic reaction, and it doesn’t mean you can’t continue treatment. Taking paracetamol on the day of infusion and for the following day or two significantly reduces the severity for most people. Staying well hydrated also helps.
Less common but important to know about: a small risk of osteonecrosis of the jaw (roughly 1 in 10,000 to 1 in 100,000 with osteoporosis-dose treatment) and a small risk of atypical femoral fracture with long-term use — both are why treatment duration is reviewed periodically rather than continued indefinitely.
We often see patients who’ve been put off bisphosphonates entirely because a tablet upset their stomach — without realising the infusion route sidesteps that problem completely. The flu-like reaction after the first dose puts some people off, but it’s predictable, manageable with paracetamol, and rarely recurs. What matters more is getting the pre-infusion checks right — kidney function, vitamin D, dental review — so the treatment works as intended. If you’re unsure whether tablets or an infusion suit you better, we talk through both during your consultation and build a plan around your treatment pathway, not a one-size-fits-all protocol.
How long does treatment continue?
Zoledronic acid is typically given once a year for 3 years, then reassessed. For many people at moderate fracture risk, a “drug holiday” follows — a period off treatment while bone density is monitored, because the drug continues to have a residual effect on bone even after infusions stop. Higher-risk patients may continue for up to 6 years before this is reconsidered. Your consultant will base this on your DEXA results, fracture history, and ongoing risk factors, not on a fixed calendar date.
Infusion vs tablets vs injections: how it compares
It’s easy to lump all osteoporosis drug delivery methods together, but they work differently:
- Oral bisphosphonates (alendronic acid, risedronate) — daily or weekly tablets, cheapest and most established, but strict dosing rules and GI side effects put some people off
- IV bisphosphonate infusion (zoledronic acid) — once yearly, avoids GI issues, requires the pre-infusion checks above
- Denosumab injection — a different drug class, given as a twice-yearly subcutaneous injection rather than a hospital infusion, with its own rebound-fracture risk if stopped abruptly
Which is right for you depends on kidney function, GI tolerance, fracture risk, and personal preference — this is exactly the kind of decision worth making with a specialist rather than guessing from general information online.
Common mistakes to avoid
- Skipping the pre-infusion blood test — kidney function can change between appointments, so this isn’t a formality
- Not correcting low vitamin D first — giving zoledronic acid to someone who is vitamin D deficient increases the risk of low blood calcium (hypocalcaemia) afterwards
- Stopping paracetamol too early — continuing it for 48–72 hours, not just on the day, controls the flu-like reaction better
- Delaying planned dental work until after, rather than before, starting treatment
- Assuming one infusion means “done” — this is a multi-year treatment plan with scheduled reviews, not a single fix
Frequently Asked Questions
Is a bone infusion painful?
No. You’ll feel a brief pinch when the cannula is inserted, similar to a blood test, but the infusion itself is not painful. Some people feel a cool sensation as the fluid enters the vein.
Can I have a bone infusion on the NHS?
Yes, zoledronic acid infusions are available on the NHS for people who meet the clinical criteria, typically after a DEXA scan confirms osteoporosis or a fragility fracture. Private clinics can also arrange infusions, often with shorter waiting times and more flexible scheduling.
What should I do if I get flu-like symptoms afterwards?
Take paracetamol as advised, stay hydrated, and rest. Symptoms typically peak within a day or two and resolve within 3 days. Contact your clinical team if symptoms are severe, last longer than a few days, or you develop a high fever.
Do I still need to take calcium and vitamin D if I have an infusion?
Yes. Infusion treatment works alongside adequate calcium and vitamin D, not instead of it. Your levels will usually be checked and corrected before treatment starts, and ongoing supplementation is often recommended.
How is a bone infusion different from a denosumab injection?
They’re different drug classes with different mechanisms. Zoledronic acid infusions are a bisphosphonate given yearly through a vein; denosumab is a separate type of drug given as a twice-yearly injection under the skin. Denosumab also carries a specific risk of rapid bone loss and rebound vertebral fractures if doses are delayed or stopped without switching to another treatment, which isn’t the case with bisphosphonates.
Can everyone with osteoporosis have a zoledronic acid infusion?
No. It’s not suitable if kidney function is significantly reduced, if you’re pregnant or breastfeeding, or if calcium levels are low and uncorrected. Your clinical team will check these before every infusion, not just the first one.
Medically reviewed by Dr. Taher Mahmud, Consultant Rheumatologist and Co-Founder, London Osteoporosis Clinic. Dr. Mahmud has over 25 years of clinical experience in bone health and osteoporosis management.
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified clinician before starting, stopping, or changing any osteoporosis treatment.
References:
[1] Black DM, et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. N Engl J Med, 2007. PubMed
[2] Reid IR, et al. Zoledronic acid and risedronate in the prevention of bone loss after denosumab discontinuation. Lancet Diabetes Endocrinol, 2020. PubMed
[3] NHS. Osteoporosis – Treatment. NHS.uk
[4] Royal Osteoporosis Society. Zoledronic acid (Aclasta). theros.org.uk
